2D DIGE

:   two‐dimensional difference gel electrophoresis

DTT

:   dithiothreitol

GIP

:   gastric inhibitory polypeptide

IEF

:   isoelectric focusing

IPG

:   immobilized pH gradient

MALDI‐TOFMS

:   matrix‐assisted laser desorption ionization--time‐of‐flight mass spectrometry

PPARα

:   peroxisome proliferator‐activated receptor alpha

PPREs

:   peroxisome proliferator response elements

TP53

:   tumor protein/suppressor p53

Fasting has been practiced for millennia in religious ceremonies among Christians, Muslims (e.g., Ramadan), Buddhism, Jews, Hindus, and others, to reduce physical activities, resulting in a state of 'quiescence' like death. It has also been practiced in clinical situations to prevent obesity, hypertension, asthma, rheumatoid arthritis, and seizures [1](#feb412497-bib-0001){ref-type="ref"}, [2](#feb412497-bib-0002){ref-type="ref"}. Moreover, in current clinical settings and basic research using animals, overnight fasting is a routine procedure before surgical operations although its influences not directly related to organs of interest or investigated parameters are often ignored [3](#feb412497-bib-0003){ref-type="ref"}.

Maintaining adequate blood levels of glucose is prerequisite for energy metabolism in glucose‐requiring organs/cells including the brain, kidney, testis, and red blood cells. Upon food deprivation, declining blood glucose levels induce rapid secretion of glucagon and decreased release of insulin, thereby activating hepatic glycogenolysis although hepatic glycogen becomes quickly (\~ 24 h) depleted. If fasting continues, peripheral organs switch as the primary energy source from glucose to fatty acids that are released from triacylglycerol droplets in adipose tissues. However, some organs/cells are unable to utilize fatty acids as an energy source, and thus, the liver produces ketone bodies from fatty acids so that such organs/cells can use them as a secondary energy source and save glucose. Meanwhile, gluconeogenesis from glucogenic amino acids of protein origin and ketogenesis from ketogenic amino acids takes place to maintain blood glucose and energy sources, respectively. Several lines of evidence suggest that all such biochemical adaptation to fasting is 'transcriptionally regulated' in the liver. The transcriptional factor/nuclear receptor proliferator peroxisome proliferator‐activated receptor alpha (PPARα) has been shown to primarily mediate adaptive responses to fasting in the liver [4](#feb412497-bib-0004){ref-type="ref"}, [5](#feb412497-bib-0005){ref-type="ref"}, [6](#feb412497-bib-0006){ref-type="ref"}, [7](#feb412497-bib-0007){ref-type="ref"}. In addition, tumor protein/suppressor p53 (TP53) has been shown recently to increase via posttranscriptional regulation in the liver upon fasting, thereby mediating amino acid catabolism and gluconeogenesis [8](#feb412497-bib-0008){ref-type="ref"}. However, such transcriptional regulation upon fasting has not been described in nonhepatic organs. Moreover, proteomic studies on the nonhepatic organs during fasting have been unexpectedly limited [9](#feb412497-bib-0009){ref-type="ref"}, [10](#feb412497-bib-0010){ref-type="ref"} although the impacts of fasting are often apparent in the nonhepatic organs as we reported fasting‐induced cardioprotection in mice [11](#feb412497-bib-0011){ref-type="ref"}.

In this study, we investigated the possible sources of organ‐specific transcriptional regulation upon fasting using two‐dimensional difference gel electrophoresis (2D DIGE) proteomic approach. Although LC‐MS/MS became the mainstream for such proteomic analysis in recent decades, conventional 2D DIGE continues to be an important technology that enables rapid and direct visualization of thousands of proteins and their quantitative analyses [12](#feb412497-bib-0012){ref-type="ref"}, [13](#feb412497-bib-0013){ref-type="ref"}, [14](#feb412497-bib-0014){ref-type="ref"}, [15](#feb412497-bib-0015){ref-type="ref"}, [16](#feb412497-bib-0016){ref-type="ref"}, [17](#feb412497-bib-0017){ref-type="ref"}, [18](#feb412497-bib-0018){ref-type="ref"}. Here, we report novel transcriptional regulation in nonhepatic organs including kidney, thymus, and spleen upon fasting for 2 days.

Materials and methods {#feb412497-sec-0002}
=====================

Animals {#feb412497-sec-0003}
-------

C57BL/6J mice were purchased from Japan SLC (Shizuoka, Japan). Eight‐week‐old male mice were group‐housed (4 mice per 470‐cm^2^ cage) in an air‐conditioned room (24 °C) kept on a 12‐h dark/light (8 pm--8 am) cycle, and allowed free access to water and a CE‐2 standard dry rodent diet (Clea Japan, Tokyo, Japan). In fasting experiments, mice were deprived of the diet for 1 or 2 days between 2 pm and 2 pm (hereinafter referred to as F1 and F2 mice, respectively). *Ad libitum*‐fed (AL) mice were analyzed as controls. After anesthetization by isoflurane inhalation, blood was collected through the heart and the liver, kidney, thymus, spleen, brain, and testis were quickly dissected out, snap‐frozen by liquid nitrogen, and stored at −80 °C. All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals, 8^th^ Edition published by the US National Research Council, and were approved by the Animal Care Committees of Keio University (No. 09187‐\[4--6\]) or Showa Pharmaceutical University (No. P‐2016‐10).

Serum biochemistry {#feb412497-sec-0004}
------------------

Serum levels of glucose and ketone bodies were measured using a Drichem 7000i biochemistry analyzer (Fujifilm, Tokyo, Japan) and an AutoWako Total Ketone Bodies clinical assay kit (Wako, Osaka, Japan), respectively. Serum levels of adiponectin, insulin, C‐peptide 2, leptin, resistin, and gastric inhibitory polypeptide (GIP; also known as glucose‐dependent insulinotropic polypeptide [19](#feb412497-bib-0019){ref-type="ref"}) were measured using Multiplex Biomarker Immunoassays for Luminex xMAP technology (Millipore, Billerica, MA, USA); Catalog Nos. MADPNMAG‐70K‐01 for adiponectin; and MMHMAG‐44k for other hormones. Quantitative analyses were performed using Luminex xPONENT and MILLIPLEX Analyst 4.2 software.

2D DIGE {#feb412497-sec-0005}
-------

Each organ aliquot (50--100 mg) was homogenized (4100 r.p.m., 30 s × 3, 4 °C) in ice‐cold urea buffer (7 [m]{.smallcaps} urea, 2 [m]{.smallcaps} thiourea, 4% CHAPS, 65 m[m]{.smallcaps} dithiothreitol \[DTT\], 1 m[m]{.smallcaps} phenylmethylsulfonyl fluoride, and 1 m[m]{.smallcaps} sodium orthovanadate) using a Micro Smash MS‐100R Beads Cell Disrupter (Tomy, Tokyo, Japan) and 5‐mm‐diameter zirconia beads (Tomy). Homogenates were centrifuged at 16 000 `g` for 5 min at 4 °C, and then, the supernatants were centrifuged at 20 000 `g` for 25 min at 4 °C. Protein concentrations of the resultant supernatants were determined using a Bio‐Rad Protein Assay and bovine serum albumin as a standard. All reagents used in this study were of analytical grades from Wako (Tokyo, Japan) or Sigma‐Aldrich unless otherwise noted. 2D DIGE was performed as described previously [12](#feb412497-bib-0012){ref-type="ref"}, [13](#feb412497-bib-0013){ref-type="ref"}, [14](#feb412497-bib-0014){ref-type="ref"}. Twenty‐five μg of protein (adjusted to pH 8.5 by adding 40 m[m]{.smallcaps} Tris/HCl \[pH 8.5\]) was labeled with 200 pmol of CyDye (Cy2, Cy3, or Cy5 minimal dye fluor \[GE Healthcare\]) for 30 min at 4 °C in the dark. A pool, to be used for calibration between the gels, was generated from equal protein amounts of all eight samples (*n* = 4 each for AL and F2 mice). The reaction was stopped by adding 0.5 μL of 10 m[m]{.smallcaps} lysine. Labeled samples were mixed, and DTT and immobilized pH gradient (IPG) buffer (final 1% each) were added for 10 min at 4 °C in the dark. The samples were subjected to isoelectric focusing (IEF) in an Immobiline DryStrip (18 cm, pH 3--10 NL \[nonlinear\], GE Healthcare) that was rehydrated for 20 h in rehydration buffer (7 [m]{.smallcaps} urea, 2 [m]{.smallcaps} thiourea, 2% Triton X‐100, 13 m[m]{.smallcaps} DTT, 2.5 m[m]{.smallcaps} acetic acid, 1% IPG buffer, and 5 p.p.m. bromophenol blue) at 20 °C, using a CoolPhoreStar IPG‐IEF Type‐PX system (Anatech, Tokyo, Japan). Once IEF was completed, the strips were equilibrated for 30 min in equilibration buffer (50 m[m]{.smallcaps} Tris/HCl \[pH 6.8\], 6 [m]{.smallcaps} urea, 2% SDS, 30% \[v/v\] glycerol, 65 m[m]{.smallcaps} DTT, and 5 p.p.m. bromophenol blue), followed by in alkylating buffer (equilibration buffer with 4.5% iodoacetamide instead of DTT) for an additional 15 min. The strips were sealed on the top of 12.5% PAGE gels (140 × 140 × 1 mm; Perfect NT Gel S from DRC, Tokyo, Japan) using 0.5% low‐melting‐point agarose in Tris/glycine electrophoresis buffer. The second dimension of protein separation was performed at a constant 200 V using an ERICA‐*S* high‐speed electrophoresis system (DRC). A total of four gels (for the comparisons between AL (*n* = 4) and F2 (*n* = 4)) were scanned at once for Cy2/Cy3/Cy5 fluorescence using a Typhoon Trio image scanner (GE Healthcare), and obtained images were integratively analyzed using DeCyder 2D ver. 6.5 differential analysis software (GE Healthcare).

Silver staining {#feb412497-sec-0006}
---------------

For protein identification using MALDI‐TOFMS, each tissue homogenate sample (100--150 μg) was subjected to 2D PAGE (mentioned above) without CyDye labeling. To get better resolutions, some samples were separated on larger 2D systems using longer strips (24 cm, pH 3--10 NL \[nonlinear\]) and larger PAGE gels (257 × 200 × 1 mm; Perfect NT Gel W from DRC). After electrophoresis, the gel was stained using a Silver Stain MS Kit (Wako).

MALDI‐TOFMS analysis of trypsin digests {#feb412497-sec-0007}
---------------------------------------

Gel pieces were excised from silver‐stained gels, destained with a mixture of destaining solutions A and B (Wako), washed twice with deionized water and four times with 50 m[m]{.smallcaps} ammonium bicarbonate (NH~4~HCO~3~):acetonitrile (1 : 1), dehydrated once with acetonitrile, twice alternately rehydrated with 100 m[m]{.smallcaps} NH~4~HCO~3~ and dehydrated with acetonitrile, and dried by vacuum centrifugation. Protein samples in the gels were digested in 10 μL of trypsin solution (0.1 μg of Trypsin Gold, Mass Spectrometry Grade \[Promega\] and 0.01% ProteaseMAX Surfactant, Trypsin Enhancer \[Promega\] in 25 m[m]{.smallcaps} NH~4~HCO~3~) by incubating at 50 °C for 1 h. Trypsin digests were mixed with 3 μL of 2% trifluoroacetic acid, and 1 μL of samples was spotted onto a μFocus MALDI plate (900 μm, 384 circles, Hudson Surface Technology \[Old Tappan, NJ, USA\]) with an equal volume of matrix solution, containing 10 m[m]{.smallcaps} α‐cyano‐4‐hydroxycinnamic acid in 1% trifluoroacetic acid/50% acetonitrile. Positive ion mass spectra were obtained using an AXIMA‐CFR plus (Shimadzu, Kyoto, Japan) in a reflectron mode. MS spectra were acquired over a mass range of 700--4000 *m*/*z* and calibrated using Peptide calibration standards (\~ 1000--3200 Da; Bruker Daltonics, Yokohama, Japan).

Database search for protein identification/clarification and upstream regulator analysis {#feb412497-sec-0008}
----------------------------------------------------------------------------------------

Proteins were identified by matching the peptide mass fingerprint with the Swiss‐Prot protein database using the MASCOT search engine (Matrix Science, <http://www.matrixscience.com>). Database searches were carried out using the following parameters: taxonomy, *Mus musculus*; enzyme, trypsin; and allowing 1 missed cleavage. Carbamidomethylation was selected as a fixed modification, and the oxidation of methionine was allowed as a variable. The peptide mass tolerance was set at 0.5 Da, and the significance threshold was set at *P* \< 0.05 probability based values on Mowse Scores (≥ 55). Protein classification by its biological process involved and its molecular function was carried out using the PANTHER (Protein ANalysis THrough Evolutionary Relationships) clarification system (<http://www.pantherdb.org/>), which is supported by a research grant from the National Institute of General Medical Sciences \[Grant GM081084\] and maintained by the group led by Paul D. Thomas at the University of Southern California. Upstream regulator analysis was performed using Ingenuity Pathway Analysis (IPA) software (Qiagen).

Statistical analysis {#feb412497-sec-0009}
--------------------

Data are expressed as mean ± SD (*n*: sample numbers). Statistical analysis was performed using one‐way ANOVA with Tukey\'s multiple comparison test with Prism ver. 5.0c software (GraphPad, La Jolla, CA, USA); *P* \< 0.05 denoted a significant difference.

Results {#feb412497-sec-0010}
=======

Protein expression changes in the liver {#feb412497-sec-0011}
---------------------------------------

We first estimated the duration required to obtain organ proteomic responses by fasting using serum biochemistry. One‐day (water‐only) fasting was sufficient to maintain minimal levels of glucose, insulin, C‐peptide 2, leptin, and resistin; the levels generally matched those in F2 mice, but, in contrast, the accumulation of ketone bodies and GIP was much more apparent in F2 mice (Fig. [1](#feb412497-fig-0001){ref-type="fig"}). Our exploratory 2D DIGE analyses did not find apparent alterations in hepatic protein expression in F1 mice (data not shown), and additional (e.g., 3‐day) fasting (that may cause acute \> 25% body weight loss) was not allowed for ethical reasons in our university. Therefore, we investigated global protein expression in various mouse organs after 2‐day fasting.

![Impact of 1‐ or 2‐day fasting on serum biochemical parameters. Serum levels of glucose, insulin, C‐peptide 2, leptin, resistin, ketone bodies, gastric inhibitory polypeptide (GIP), and adiponectin were measured. AL,*ad libitum*‐fed (AL); F1, 1‐day fasted; F2, 2‐day fasted. Data are mean ± SD (*n*: sample numbers); significant changes in \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 vs AL; ^\#\#\#^ *P* \< 0.001 vs F1 by one‐way ANOVA with Tukey\'s multiple comparison test.](FEB4-8-1524-g001){#feb412497-fig-0001}

We reported previously that 2‐day fasting of adult C57BL/6J male mice causes 23.4% body and 32.2% liver weight losses [20](#feb412497-bib-0020){ref-type="ref"}. Despite such drastic alterations, the marked activation of protein degradation systems such as ubiquitin‐proteasome and autophagy‐lysosome systems was not detectable by RT‐PCR analysis of the liver, which highly contrasted with thymus, another highly atrophied (54.7% weight loss) organ [20](#feb412497-bib-0020){ref-type="ref"}. However, our 2D DIGE proteomic analyses revealed substantial numbers of proteins were up‐ or downregulated in the liver of F2 mice; for example, among a total of 1824 protein spots identified in the representative 2D gel (Fig. [2](#feb412497-fig-0002){ref-type="fig"}A), 214 (11.7%, red circles) and 178 (9.8%, green circles) spots were \> 1.1‐fold up‐ and downregulated, respectively (Fig. [2](#feb412497-fig-0002){ref-type="fig"}B). By comparative analysis between the four independent gels using DeCyder software, we identified 34 significantly upregulated proteins (*P* \< 0.05, Table [1](#feb412497-tbl-0001){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet A\] for weblinks); these include key enzymes in gluconeogenesis (phosphoenolpyruvate carboxykinase, cytosolic \[Pck1 (spot 1), the rate‐limiting enzyme of gluconeogenesis\] and pyruvate carboxylase, mitochondrial \[Pc (spot 18)\]), peroxisomal fatty acid β‐oxidation (peroxisomal acyl‐CoA oxidase 1 \[Acox1 (spot 10)\]), ketogenesis (hydroxymethylglutaryl‐CoA synthase, mitochondrial \[Hmgcs2 (spot 12, 12′), the rate‐limiting enzyme of ketogenesis\] [21](#feb412497-bib-0021){ref-type="ref"}, [22](#feb412497-bib-0022){ref-type="ref"}), phenylalanine metabolism (phenylalanine‐4‐hydroxylase \[Pah (spot 9)\] and homogentisate 1,2‐dioxygenase \[Hgd (spot 7)\]), and *S*‐adenosylmethionine (the major methyl donor for hundreds of methyltransferases) synthesis (*S*‐adenosylmethionine synthase isoform type‐1 \[Mat1a (spots 2, 2′, 2′′, 2′′′)\]). We also identified 38 significantly downregulated proteins involved in fatty acid synthesis (fatty acid synthase \[Fasn (spot 37)\]), glycogenolysis (glycogen phosphorylase, liver form \[Pygl (spot 40)\], and glutathione conjugation (glutathione *S*‐transferases, π1 \[Gstp1 (spot 54)\]), and μ1 \[Gstm1 (spot 70)\] (Table [1](#feb412497-tbl-0001){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet A\]).

![Fasting‐induced protein remodeling in the liver. Fluorescent 2D DIGE was performed on liver homogenates from *ad libitum*‐fed (AL) and 2‐day fasted (F2) mice. (A) Representative fluorescent gel image in which proteins upregulated by fasting are labeled in red and those downregulated are in green. Approximate isoelectric points (p*I*) and molecular weights (MW;kDa) are indicated. (B) Quantitative profiling of the above image using DeCyder software. Upregulated and downregulated (\> 1.1‐fold) protein spots are labeled in red and green, respectively, with others in yellow. The *x*‐axis represents log \[(Fasted/AL) fold induction\], and the *y*‐axis represents spot signal intensity; the red line represents spot number distribution, while the blue line its Gaussian approximation; and two black straight lines represent 1.1 and --1.1 fold change. (C) The three highest scoring upstream regulators (PPARα, NR1I2, and PPARγ) listed by Ingenuity Pathway Analysis (IPA) of the samples from AL and F2 mice (*n* = 4 each). Upregulated proteins with IDs identical to those in A and B are shown in red and downregulated proteins are in green, and predicted relationships are indicated by various types of lines described in the panel. The numbers in parentheses are the numbers of current publications reporting those relationships.](FEB4-8-1524-g002){#feb412497-fig-0002}

###### 

Protein expression changes upon 48‐h fasting in mouse liver

  Liver Spot ID            Fold change   *P*‐value   Protein name                                                               Uniprot ID         Gene name   Unigene ID   Mascot score   Sequence coverage   Peptide matches   MW        p*I*
  ------------------------ ------------- ----------- -------------------------------------------------------------------------- ------------------ ----------- ------------ -------------- ------------------- ----------------- --------- ------
  Upregulated proteins                                                                                                                                                                                                                     
  1                        2.89          0.003       Phosphoenolpyruvate carboxykinase, cytosolic (GTP)                         [Q9Z2V4](Q9Z2V4)   Pck1        Mm.266867    132            50%                 30/90             70 051    6.18
  1′                       2.83          0.003       Phosphoenolpyruvate carboxykinase, cytosolic (GTP)                         [Q9Z2V4](Q9Z2V4)   Pck1        Mm.266867    181            50%                 27/55             70 051    6.18
  2                        2.66          0.003       S‐adenosylmethionine synthase isoform type‐1                               [Q91X83](Q91X83)   Mat1a       Mm.14064     76             24%                 9/32              44 051    5.51
  2′                       2.51          0.003       S‐adenosylmethionine synthase isoform type‐1                               [Q91X83](Q91X83)   Mat1a       Mm.14064     64             35%                 13/83             44 051    5.51
  3                        2.03          0.003       Apolipoprotein A‐I                                                         [Q00623](Q00623)   Apoa1       Mm.26743     172            48%                 16/23             30 597    5.51
  4                        2.01          0.011       Aspartate aminotransferase, cytoplasmic                                    [P05201](P05201)   Got1        Mm.19039     211            60%                 24/46             46 504    6.68
  5                        1.97          0.010       Ornithine aminotransferase, mitochondrial                                  [P29758](P29758)   Oat         Mm.13694     147            53%                 24/95             48 723    6.19
  2′′                      1.94          0.009       S‐adenosylmethionine synthase isoform type‐1                               [Q91X83](Q91X83)   Mat1a       Mm.14064     106            28%                 10/17             44 051    5.51
  6                        1.93          0.003       Dimethylglycine dehydrogenase, mitochondrial                               [Q9DBT9](Q9DBT9)   Dmgdh       Mm.21789     109            27%                 15/32             97 422    7.69
  7                        1.92          0.005       Homogentisate 1,2‐dioxygenase                                              [Q05BJ1](Q05BJ1)   Hgd         Mm.157442    61             17%                 8/31              50 726    6.86
  8                        1.89          0.011       Serum albumin                                                              [P07724](P07724)   Alb         Mm.16773     168            29%                 15/17             70 700    5.75
  8′                       1.87          0.025       Serum albumin                                                              [P07724](P07724)   Alb         Mm.16773     157            52%                 33/113            70 700    5.75
  2′′′                     1.85          0.004       S‐adenosylmethionine synthase isoform type‐1                               [Q91X83](Q91X83)   Mat1a       Mm.14064     65             22%                 7/15              44 051    5.51
  8′′                      1.80          0.023       Serum albumin                                                              [P07724](P07724)   Alb         Mm.16773     61             18%                 9/25              70 700    5.75
  9                        1.63          0.010       Phenylalanine‐4‐hydroxylase                                                [P16331](P16331)   Pah         Mm.342177    78             28%                 12/36             52 381    5.91
  10                       1.62          0.003       Peroxisomal acyl‐coenzyme A oxidase 1                                      [Q9R0H0](Q9R0H0)   Acox1       Mm.356689    73             27%                 13/39             75 000    8.64
  11                       1.59          0.022       Elongation factor 2                                                        [P58252](P58252)   Eef2        Mm.326799    153            47%                 33/74             96 222    6.41
  12                       1.58          0.003       Hydroxymethylglutaryl‐CoA synthase, mitochondrial                          [P54869](P54869)   Hmgcs2      Mm.289131    103            25%                 13/29             57 300    8.65
  13                       1.55          0.013       Annexin A6                                                                 [P14824](P14824)   Anxa6       Mm.265347    85             26%                 15/32             76 294    5.34
  14                       1.54          0.004       Alpha‐aminoadipic semialdehyde synthase, mitochondrial                     [Q99K67](Q99K67)   Aass        Mm.18651     71             36%                 23/86             103 650   6.42
  15                       1.51          0.003       Stress‐70 protein, mitochondrial                                           [P38647](P38647)   Hspa9       Mm.209419    104            35%                 17/43             73 701    5.81
  8′′′                     1.50          0.034       Serum albumin                                                              [P07724](P07724)   Alb         Mm.16773     171            54%                 24/78             70 700    5.75
  12′                      1.44          0.004       Hydroxymethylglutaryl‐CoA synthase, mitochondrial                          [P54869](P54869)   Hmgcs2      Mm.289131    101            39%                 16/46             57 300    8.65
  16                       1.44          0.004       Transketolase                                                              [Q62371](Q62371)   Tkt         Mm.290692    72             20%                 9/28              68 272    7.23
  17                       1.40          0.008       Apolipoprotein E                                                           [P08226](P08226)   Apoe        Mm.305152    98             38%                 15/32             35 901    5.56
  9′                       1.35          0.003       Phenylalanine‐4‐hydroxylase                                                [P16331](P16331)   Pah         Mm.342177    88             28%                 11/35             52 381    5.91
  18                       1.35          0.004       Pyruvate carboxylase, mitochondrial                                        [P06802](P06802)   Pc          Mm.342177    120            16%                 15/20             130 344   6.25
  19                       1.35          0.008       60 kDa heat shock protein, mitochondrial                                   [P63038](P63038)   Hspd1       Mm.1777      72             33%                 15/48             61 088    5.91
  20                       1.35          0.016       Keratin, type II cytoskeletal                                              [P11679](P11679)   Krt8        Mm.358618    146            35%                 18/26             54 531    5.70
  21                       1.31          0.016       Aconitate hydratase, mitochondrial                                         [Q99KI0](Q99KI0)   Aco2        Mm.154581    93             13%                 9/15              86 151    8.08
  22                       1.28          0.022       4‐aminobutyrate aminotransferase, mitochondrial                            [P61922](P61922)   Abat        Mm.259315    58             25%                 11/40             57 100    8.35
  23                       1.27          0.004       Succinate dehydrogenase (ubiquinone) flavoprotein subunit, mitochondrial   [Q8K2B3](Q8K2B3)   Sdha        Mm.158231    216            61%                 28/59             73 623    7.06
  24                       1.27          0.013       Dihydropyrimidine dehydrogenase \[NADP(+)\]                                [Q80XT4](Q80XT4)   Dpyd        Mm.27907     90             20%                 16/33             113 177   7.13
  25                       1.27          0.018       3‐mercaptopyruvate sulfurtransferase                                       [Q99J99](Q99J99)   Mpst        Mm.294215    64             32%                 9/27              33 231    6.11
  26                       1.25          0.003       2‐oxoglutarate dehydrogenase, mitochondrial                                [Q60597](Q60597)   Ogdh        Mm.276348    80             17%                 18/44             117 572   6.36
  27                       1.25          0.003       Clathrin heavy chain 1                                                     [Q68FD5](Q68FD5)   Cltc        Mm.254588    58             6%                  12/18             193 202   5.48
  28                       1.24          0.013       Keratin, type I cytoskeletal 12                                            [Q64291](Q64291)   Krt12       Mm.436651    63             21%                 7/106             52 774    4.76
  29                       1.23          0.016       Argininosuccinate lyase                                                    [Q91YI0](Q91YI0)   Asl         Mm.23869     192            56%                 29/71             51 878    6.48
  30                       1.23          0.039       4‐hydroxyphenylpyruvate dioxygenase                                        [P49429](P49429)   Hpd         Mm.439709    239            72%                 32/95             45 254    6.58
  11′                      1.21          0.022       Elongation factor 2                                                        [P58252](P58252)   Eef2        Mm.326799    152            43%                 28/55             96 222    6.41
  31                       1.19          0.036       Keratin, type I cytoskeletal                                               [P05784](P05784)   Krt18       Mm.22479     133            35%                 16/24             47 509    5.22
  32                       1.16          0.003       Hydroxyacyl‐coenzyme A dehydrogenase, mitochondrial                        [O08756](O08756)   Hadh        Mm.260164    61             24%                 7/29              34 613    8.76
  33                       1.16          0.005       Apoptosis‐inducing factor 1, mitochondrial                                 [Q9Z0X1](Q9Z0X1)   Aifm1       Mm.240434    63             16%                 8/19              66 952    9.23
  34                       1.14          0.020       Sarcosine dehydrogenase, mitochondrial                                     [Q99LB7](Q99LB7)   Sardh       Mm.278467    58             20%                 18/57             102 644   6.28
  Downregulated proteins                                                                                                                                                                                                                   
  35                       −2.58         0.044       Major urinary protein 2                                                    [P11589](P11589)   Mup2        Mm.457980    152            77%                 17/36             20 935    5.04
  36                       −2.38         0.003       DENN domain‐containing protein 2A                                          [B7ZP28](B7ZP28)   Dennd2a     Mm.440021    57             8%                  9/19              113 936   9.07
  35′                      −2.01         0.027       Major urinary protein 2                                                    [P11589](P11589)   Mup2        Mm.457980    79             43%                 8/23              20 935    5.04
  37                       −1.88         0.008       Fatty acid synthase                                                        [P19096](P19096)   Fasn        Mm.236443    227            36%                 85/131            274 994   6.13
  38                       −1.66         0.030       Pyrethroid hydrolase Ces2a                                                 [Q8QZR3](Q8QZR3)   Ces2a       Mm.212983    188            58%                 27/59             62 356    5.74
  39                       −1.64         0.014       Selenium‐binding protein 2                                                 [Q63836](Q63836)   Selenbp2    Mm.225405    68             18%                 10/31             53 147    5.78
  40                       −1.63         0.003       Glycogen phosphorylase, liver form                                         [Q9ET01](Q9ET01)   Pygl        Mm.256926    66             14%                 11/21             97 857    6.63
  41                       −1.60         0.040       78 kDa glucose‐regulated protein                                           [P20029](P20029)   Hspa5       Mm.330160    202            41%                 24/36             72 492    5.07
  42                       −1.60         0.010       Carbonic anhydrase 3                                                       [P16015](P16015)   Car3        Mm.300       86             41%                 8/19              29 633    6.89
  43                       −1.60         0.007       26S protease regulatory subunit 6B                                         [P54775](P54775)   Psmc4       Mm.29582     130            68%                 21/95             47 493    5.09
  44                       −1.53         0.005       Hypoxia upregulated protein 1                                              [Q9JKR6](Q9JKR6)   Hyou1       Mm.116721    145            17%                 19/22             111 340   5.12
  45                       −1.50         0.017       NADH dehydrogenase (ubiquinone) flavoprotein 2, mitochondrial              [Q9D6J6](Q9D6J6)   Ndufv2      Mm.2206      58             36%                 6/23              27 610    7.00
  46                       −1.47         0.016       Calreticulin                                                               [P14211](P14211)   Calr        Mm.1971      87             22%                 9/17              48 136    4.33
  41′                      −1.46         0.019       78 kDa glucose‐regulated protein                                           [P20029](P20029)   Hspa5       Mm.330160    64             16%                 10/23             72 492    5.07
  47                       −1.46         0.003       Endoplasmin                                                                [P08113](P08113)   Hsp90b1     Mm.87773     57             13%                 12/21             92 703    4.74
  48                       −1.44         0.017       Formimidoyltransferase‐cyclodeaminase                                      [Q91XD4](Q91XD4)   Ftcd        Mm.36278     78             41%                 17/73             59 529    5.79
  49                       −1.44         0.006       Indolethylamine *N*‐methyltransferase                                      [P40936](P40936)   Inmt        Mm.299       108            48%                 13/46             30 068    6.00
  46′                      −1.43         0.024       Calreticulin                                                               [P14211](P14211)   Calr        Mm.1971      80             29%                 12/36             48 136    4.33
  50                       −1.43         0.022       Carboxylesterase 3A                                                        [Q63880](Q63880)   Ces3a       Mm.295534    94             23%                 14/39             63 677    5.78
  40′                      −1.42         0.017       Glycogen phosphorylase, liver form                                         [Q9ET01](Q9ET01)   Pygl        Mm.256926    169            35%                 24/36             97 857    6.63
  51                       −1.42         0.016       Cytosolic 10‐formyltetrahydrofolate dehydrogenase                          [Q8R0Y6](Q8R0Y6)   Aldh1 l1    Mm.30035     62             9%                  7/9               99 502    5.64
  51′                      −1.41         0.003       Cytosolic 10‐formyltetrahydrofolate dehydrogenase                          [Q8R0Y6](Q8R0Y6)   Aldh1 l1    Mm.30035     338            76%                 54/97             99 502    5.64
  52                       −1.39         0.016       Putative [l]{.smallcaps}‐aspartate dehydrogenase                           [Q9DCQ2](Q9DCQ2)   Aspdh       Mm.88478     66             39%                 9/38              30 479    6.45
  53                       −1.39         0.009       Sorbitol dehydrogenase                                                     [Q64442](Q64442)   Sord        Mm.371580    108            35%                 9/22              38 795    6.56
  54                       −1.38         0.016       Glutathione *S*‐transferase π1                                             [P19157](P19157)   Gstp1       Mm.299292    73             44%                 10/42             23 765    7.68
  51′′                     −1.37         0.004       Cytosolic 10‐formyltetrahydrofolate dehydrogenase                          [Q8R0Y6](Q8R0Y6)   Aldh1 l1    Mm.30035     235            38%                 28/37             99 502    5.64
  55                       −1.36         0.006       Protein disulfide‐isomerase A3                                             [P27773](P27773)   Pdia3       Mm.263177    141            41%                 19/43             57 099    5.88
  54′                      −1.33         0.009       Glutathione *S*‐transferase π1                                             [P19157](P19157)   Gstp1       Mm.299292    87             53%                 11/47             23 765    7.68
  56                       −1.32         0.005       DDRGK domain‐containing protein 1                                          [Q80WW9](Q80WW9)   Ddrgk1      Mm.440063    55             21%                 5/15              35 956    5.32
  57                       −1.32         0.037       Regucalcin                                                                 [Q64374](Q64374)   Rgn         Mm.2118      192            71%                 20/55             33 899    5.15
  58                       −1.32         0.014       Carboxylesterase 1D                                                        [Q8VCT4](Q8VCT4)   Ces1d       Mm.292803    110            36%                 17/67             62 034    6.17
  59                       −1.31         0.009       Heat shock protein HSP 90‐beta                                             [P11499](P11499)   Hsp90ab1    Mm.2180      89             19%                 13/27             83 571    4.97
  38′                      −1.30         0.023       Pyrethroid hydrolase Ces2a                                                 [Q8QZR3](Q8QZR3)   Ces2a       Mm.212983    63             13%                 6/8               62 356    5.74
  60                       −1.29         0.034       C‐1‐tetrahydrofolate synthase, cytoplasmic                                 [Q922D8](Q922D8)   Mthfd1      Mm.29584     168            43%                 32/71             101 820   6.70
  61                       −1.29         0.005       T‐complex protein 1 subunit beta                                           [P80314](P80314)   Cct2        Mm.247788    58             20%                 9/26              57 783    5.97
  62                       −1.28         0.010       Lactoylglutathione lyase                                                   [Q9CPU0](Q9CPU0)   Glo1        Mm.261984    99             66%                 13/87             20 967    5.24
  63                       −1.26         0.005       3‐hydroxyanthranilate 3,4‐dioxygenase                                      [Q78JT3](Q78JT3)   Haao        Mm.30100     105            33%                 10/18             32 955    6.09
  50′                      −1.24         0.026       Carboxylesterase 3A                                                        [Q63880](Q63880)   Ces3a       Mm.295534    61             16%                 8/21              63 677    5.78
  42′                      −1.24         0.019       Carbonic anhydrase 3                                                       [P16015](P16015)   Car3        Mm.300       85             63%                 15/83             29 633    6.89
  64                       −1.23         0.003       Nucleoside diphosphate kinase B                                            [Q01768](Q01768)   Nme2        Mm.1260      62             59%                 7/32              17 466    6.97
  65                       −1.22         0.023       Catalase                                                                   [P70423](P70423)   Cat         Mm.4215      115            22%                 12/21             60 043    7.72
  66                       −1.21         0.039       Cytoplasmic aconitate hydratase                                            [P28271](P28271)   Aco1        Mm.331547    223            52%                 37/77             98 691    7.23
  67                       −1.20         0.009       Peroxiredoxin‐1                                                            [P35700](P35700)   Prdx1       Mm.30929     90             47%                 9/27              22 390    8.26
  68                       −1.18         0.038       Acyl‐CoA synthetase family member 2, mitochondrial                         [Q8VCW8](Q8VCW8)   Acsf2       Mm.386885    134            49%                 25/96             68 591    8.44
  69                       −1.18         0.011       Methylmalonyl‐CoA mutase, mitochondrial                                    [P16332](P16332)   Mut         Mm.259884    79             36%                 19/64             83 248    6.45
  70                       −1.18         0.009       Glutathione *S*‐transferase μ1                                             P10649             Gstm1       Mm.37199     169            77%                 21/49             26 067    7.71
  71                       −1.14         0.027       Glyceraldehyde‐3‐phosphate dehydrogenase                                   [P16858](P16858)   Gapdh       Mm.304088    75             50%                 16/68             36 072    8.44
  72                       −1.11         0.034       Selenium‐binding protein 1                                                 [P17563](P17563)   Selenbp1    Mm.196558    104            25%                 12/21             53 051    5.87
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Proteomic data analysis using IPA software revealed PPARα (= PPARA) as the highest scoring upstream regulator, followed by nuclear receptor subfamily 1 group I member 2 (NR1I2; also known as PXR \[pregnane X receptor\]) and peroxisome proliferator‐activated receptor gamma (PPARG = PPARγ) (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]). Among multiple PPARα‐regulated proteins [23](#feb412497-bib-0023){ref-type="ref"}, [24](#feb412497-bib-0024){ref-type="ref"}, a total of 20 up‐ or downregulated proteins were identified (Fig. [2](#feb412497-fig-0002){ref-type="fig"}C). Moreover, among NR1I2‐ and PPARγ‐regulated proteins, 10 and 14 up‐ or downregulated proteins were identified, respectively (Fig. [2](#feb412497-fig-0002){ref-type="fig"}C), some of which might contribute to their relatively high scores (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]). In addition, TP53 was listed as the fourth highest scoring regulator in the liver by regulating expression of 19 proteins (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]).

Protein expression changes in the kidney {#feb412497-sec-0012}
----------------------------------------

Two‐day fasting induced 18.6% kidney weight loss with no or mild activation of protein degradation systems in our previous RT‐PCR analysis [20](#feb412497-bib-0020){ref-type="ref"}. Proteomic analysis revealed a total of 1633 spots in the representative 2D gel (Fig. [3](#feb412497-fig-0003){ref-type="fig"}A), of which 45 (2.76%, red circles) and 44 (2.69%, green circles) spots were \> 1.1‐fold up‐ and downregulated, respectively (Fig. [3](#feb412497-fig-0003){ref-type="fig"}B). We identified only 12 significantly upregulated proteins in the kidney of F2 mice, which included Pck1 (spot 1), Acox1 (spot 3), and apolipoprotein A‐I (Apoa1, spot 4), just like in the liver (Table [2](#feb412497-tbl-0002){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet A and B\]). We also identified 20 significantly downregulated proteins in the kidney; most of them (except calreticulin \[Calr (spot 15)\] and endoplasmin \[Hsp90b1 (heat shock protein 90 kDa beta member 1, spot 16)\]) were not apparently changed in the liver (Table [2](#feb412497-tbl-0002){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet A and B\]). Nevertheless, the upstream regulator analysis revealed PPARα as the second highest scoring upstream regulator after ATF6 (activating transcriptional factor 6) and followed by KLF15 (Krüppel‐like factor 15) (Fig. [3](#feb412497-fig-0003){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet B\]).

![Fasting‐induced protein remodeling in the kidney. Fluorescent 2D DIGE was performed on kidney homogenates from *ad libitum*‐fed (AL) and 2‐day fasted (F2) mice. (A) Representative fluorescent gel image in which proteins upregulated by fasting are labeled in red and those downregulated are in green. (B) Quantitative profiling of the above image using DeCyder. (C) The three highest scoring upstream regulators (ATF6, PPARα, and KLF15) listed by IPA of the samples from AL and F2 mice (*n* = 4 each). Refer to Fig. [2](#feb412497-fig-0002){ref-type="fig"} legend for detailed information.](FEB4-8-1524-g003){#feb412497-fig-0003}

###### 

Protein expression changes upon 48‐h fasting in mouse kidney

  Kidney spot ID                            Fold change        *P*‐VALUE   Protein name                                                   Uniprot ID         Gene name   Unigene ID   Mascot score   Sequence coverage   Peptide matches   MW        p*I*
  ----------------------------------------- ------------------ ----------- -------------------------------------------------------------- ------------------ ----------- ------------ -------------- ------------------- ----------------- --------- ------
  Upregulated proteins                                                                                                                                                                                                                               
  1                                         3.67               0.004       Phosphoenolpyruvate carboxykinase, cytosolic (GTP)             [Q9Z2V4](Q9Z2V4)   Pck1        Mm.266867    183            53%                 31/77             70 051    6.18
  2                                         1.59               0.004       *N*‐acetylglucosaminyl‐phosphatidylinositol de‐*N*‐acetylase   [Q5SX19](Q5SX19)   Pigl        Mm.390358    61             39%                 7/28              28 450    8.59
  3                                         1.50               0.014       Peroxisomal acyl‐coenzyme A oxidase 1                          [Q9R0H0](Q9R0H0)   Acox1       Mm.356689    121            33%                 15/29             75 000    8.64
  4                                         1.48               0.018       Apolipoprotein A‐I                                             [Q00623](Q00623)   Apoa1       Mm.26743     111            39%                 14/35             30 597    5.51
  5                                         1.43               0.011       Mixture: Acyl‐coenzyme A thioesterase 1                        [O55137](O55137)   Acot1       Mm.1978      79             39%                 11/38             46 335    6.12
  Mixture: Acyl‐coenzyme A thioesterase 2   [Q9QYR9](Q9QYR9)   Acot2       Mm.371675                                                      65                 32%         10/38        49 854         6.88                                            
  6                                         1.32               0.028       Carnitine O‐palmitoyltransferase 2, mitochondrial              [P52825](P52825)   Cpt2        Mm.307620    59             27%                 12/44             74 504    8.59
  7                                         1.19               0.018       Glutathione *S*‐transferase τ2                                 [Q61133](Q61133)   Gstt2       Mm.24118     87             41%                 9/26              27 731    7.02
  8                                         1.14               0.034       Stress‐70 protein, mitochondrial                               [P38647](P38647)   Hspa9       Mm.209419    106            46%                 24/73             73 701    5.81
  9                                         1.14               0.004       Villin‐1                                                       [Q62468](Q62468)   Vil1        Mm.471601    155            27%                 20/28             93 230    5.72
  9′                                        1.14               0.017       Villin‐1                                                       [Q62468](Q62468)   Vil1        Mm.471601    159            35%                 27/44             93 230    5.72
  10                                        1.12               0.027       Glutathione *S*‐transferase μ1                                 [P10649](P10649)   Gstm1       Mm.37199     120            69%                 17/50             26 067    7.71
  11                                        1.11               0.034       Selenium‐binding protein 1                                     [P17563](P17563)   Selenbp1    Mm.196558    208            51%                 20/29             53 051    5.87
  12                                        1.11               0.044       Cytosolic 10‐formyltetrahydrofolate dehydrogenase              [Q8R0Y6](Q8R0Y6)   Aldh1 l1    Mm.30035     238            49%                 37/65             99 502    5.64
  Downregulated proteins                                                                                                                                                                                                                             
  13                                        −1.84              0.004       Inositol oxygenase                                             [Q9QXN5](Q9QXN5)   Miox        Mm.158200    108            55%                 13/47             33 484    5.03
  14                                        −1.56              0.004       Glycine amidinotransferase, mitochondrial                      [Q9D964](Q9D964)   Gatm        Mm.29975     150            32%                 16/30             48 779    8.00
  15                                        −1.32              0.035       Calreticulin                                                   [P14211](P14211)   Calr        Mm.1971      100            27%                 13/30             48 136    4.33
  16                                        −1.31              0.004       Endoplasmin                                                    [P08113](P08113)   Hsp90b1     Mm.87773     74             14%                 14/21             92 703    4.74
  17                                        −1.29              0.023       Phenylalanine‐4‐hydroxylase                                    [P16331](P16331)   Pah         Mm.263539    69             31%                 13/50             52 381    5.91
  18                                        −1.28              0.027       Acyl‐coenzyme A synthetase ACSM2, mitochondrial                [Q8K0L3](Q8K0L3)   Acsm2       Mm.268448    215            40%                 22/28             64 741    8.54
  19                                        −1.26              0.014       Elongation factor 2                                            [P58252](P58252)   Eef2        Mm.326799    65             12%                 9/13              96 222    6.41
  20                                        −1.22              0.027       Sulfite oxidase, mitochondrial                                 [Q8R086](Q8R086)   Suox        Mm.23352     62             14%                 7/15              61 231    6.07
  21                                        −1.20              0.009       Elongation factor Tu, mitochondrial                            [Q8BFR5](Q8BFR5)   Tufm        Mm.197829    70             16%                 8/14              49 876    7.23
  22                                        −1.19              0.050       Gelsolin                                                       [P13020](P13020)   Gsn         Mm.21109     72             26%                 12/38             86 287    5.83
  18′                                       −1.19              0.019       Acyl‐coenzyme A synthetase ACSM2, mitochondria                 [Q8K0L3](Q8K0L3)   Acsm2       Mm.268448    114            49%                 22/94             64 741    8.54
  23                                        −1.18              0.049       Nucleolin                                                      [Q91VA3](Q91VA3)   Ncl         Mm.154378    61             10%                 7/12              76 734    4.69
  24                                        −1.18              0.023       Acetyl‐coenzyme A synthetase 2‐like, mitochondrial             [Q99NB1](Q99NB1)   Acss1       Mm.7044      60             16%                 10/27             75 317    6.51
  25                                        −1.18              0.019       Beta‐lactamase‐like protein 2                                  [Q99KR3](Q99KR3)   Lactb2      Mm.89572     81             34%                 7/13              33 019    5.89
  19′                                       −1.17              0.049       Elongation factor 2                                            [P58252](P58252)   Eef2        Mm.326799    60             17%                 14/37             96 222    6.41
  26                                        −1.17              0.043       Heat shock protein 75 kDa, mitochondrial                       [Q9CQN1](Q9CQN1)   Trap1       Mm.123366    147            44%                 25/49             80 501    6.25
  27                                        −1.17              0.009       2‐oxoglutarate dehydrogenase, mitochondrial                    [Q60597](Q60597)   Ogdh        Mm.276348    155            24%                 23/40             117 572   6.36
  28                                        −1.16              0.049       4‐trimethylaminobutyraldehyde dehydrogenase                    [Q9JLJ2](Q9JLJ2)   Aldh9a1     Mm.330055    67             23%                 10/27             54 449    6.63
  29                                        −1.15              0.031       Lon protease homolog, mitochondrial                            [Q56A16](Q56A16)   Lonp1       Mm.329136    63             15%                 14/29             106 347   6.15
  30                                        −1.13              0.039       3‐hydroxyisobutyrate dehydrogenase, mitochondrial              [Q99L13](Q99L13)   Hibadh      Mm.286458    78             21%                 7/12              35 816    8.37
  31                                        −1.13              0.018       EH domain‐containing protein 1                                 [Q9WVK4](Q9WVK4)   Ehd1        Mm.30169     60             21%                 10/26             60 622    6.35
  32                                        −1.12              0.034       Isovaleryl‐CoA dehydrogenase, mitochondrial                    [Q9JHI5](Q9JHI5)   Ivd         Mm.6635      106            38%                 13/27             46 695    8.53
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Protein expression changes in the thymus and spleen {#feb412497-sec-0013}
---------------------------------------------------

Two‐day fasting induced marked weight loss in both the thymus and spleen (54.7% and 41.2%, respectively) although protein degradation systems were only found to be highly activated in the thymus but not in the spleen [20](#feb412497-bib-0020){ref-type="ref"}. In a representative 2D gel, among a total of 1874 spots detected in the thymus (Fig. [4](#feb412497-fig-0004){ref-type="fig"}A), 54 (2.88%, red circles) and 67 (3.57%, green circles) spots were found to be up‐ or downregulated, respectively (Fig. [4](#feb412497-fig-0004){ref-type="fig"}B). We identified 10 and 16 significantly up‐ and downregulated proteins in the thymus, respectively; the former includes several structural proteins such as keratin, collagen, annexin, actin, and moesin (Table [3](#feb412497-tbl-0003){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet C\]). Upstream regulators included MYCN (*v*‐myc myelocytomatosis viral‐related oncogene, neuroblastoma derived \[avian\]), TP53, and huntingtin (HTT) in this order (Fig. [4](#feb412497-fig-0004){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet C\]). In a representative 2D gel, among a total of 1861 spots detected in the spleen (Fig. [5](#feb412497-fig-0005){ref-type="fig"}A), 42 (2.26%, red circles) and 34 (1.83%, green circles) spots were found to be up‐ or downregulated, respectively (Fig. [5](#feb412497-fig-0005){ref-type="fig"}B). We could identify only five and nine significantly up‐ and downregulated proteins in the spleen, respectively (Table [4](#feb412497-tbl-0004){ref-type="table"} and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet D\]), although the upstream regulators included TP53 with the highest score, followed by nuclear factor of NFKBIA (kappa light polypeptide gene enhancer in B‐cell inhibitor, alpha) and RARB (retinoic acid receptor, beta) (Fig. [5](#feb412497-fig-0005){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet D\]).

![Fasting‐induced protein remodeling in the thymus. Fluorescent 2D DIGE was performed on thymus homogenates from *ad libitum*‐fed (AL) and 2‐day fasted (F2) mice. (A) Representative fluorescent gel image in which proteins upregulated by fasting are labeled in red and those downregulated are in green. (B) Quantitative profiling of the above image using DeCyder. (C) The three highest scoring upstream regulators (MYCN,TP53, and HTT) listed by IPA of the samples from AL and F2 mice (*n* = 4 each). Refer to Fig. [2](#feb412497-fig-0002){ref-type="fig"} legend for detailed information.](FEB4-8-1524-g004){#feb412497-fig-0004}

###### 

Protein expression changes upon 48‐h fasting in mouse thymus

  Thymus spot ID           Fold change   *P*‐value   Protein name ID                                            Uniprot name       Gene ID    Unigene score   Mascot   Sequence coverage   Peptide matches   MW        p*I*
  ------------------------ ------------- ----------- ---------------------------------------------------------- ------------------ ---------- --------------- -------- ------------------- ----------------- --------- ------
  Upregulated proteins                                                                                                                                                                                                 
  1                        1.82          0.031       Keratin, type II cytoskeletal 8                            [P11679](P11679)   Krt8       Mm.358618       146      52%                 30/66             54 531    5.70
  2                        1.71          0.031       Collagen alpha‐1 (VI) chain                                [Q04857](Q04857)   Col6a1     Mm.2509         109      40%                 31/98             109 562   5.20
  1′                       1.70          0.042       Keratin, type II cytoskeletal 8                            [P11679](P11679)   Krt8       Mm.358618       163      48%                 24/43             54 531    5.70
  3                        1.61          0.018       Keratin, type I cytoskeletal 18                            [P05784](P05784)   Krt18      Mm.22479        120      40%                 17/41             47 509    5.22
  4                        1.54          0.024       Annexin A4                                                 [P97429](P97429)   Anxa4      Mm.259702       85       61%                 18/76             36 178    5.43
  5                        1.51          0.049       Proteasome subunit beta type‐10                            [O35955](O35955)   Psmb10     Mm.787          72       56%                 9/54              29 330    6.40
  6                        1.38          0.020       Heterogeneous nuclear ribonucleoprotein F                  [Q9Z2X1](Q9Z2X1)   Hnrnpf     Mm.422979       122      53%                 15/64             46 043    5.31
  7                        1.37          0.049       Actin, cytoplasmic 1                                       [P60710](P60710)   Actb       Mm.391967       63       57%                 12/65             42 052    5.29
  8                        1.29          0.018       Serpin B6                                                  [Q60854](Q60854)   Serpinb6   Mm.252210       59       40%                 13/67             42 913    5.53
  9                        1.24          0.050       Gelsolin                                                   [P13020](P13020)   Gsn        Mm.21109        85       34%                 19/71             86 287    5.83
  10                       1.21          0.050       Moesin                                                     [P26041](P26041)   Msn        Mm.138876       124      48%                 29/71             67 839    6.22
  10′                      1.17          0.049       Moesin                                                     [P26041](P26041)   Msn        Mm.138876       59       45%                 25/122            67 839    6.22
  Downregulated proteins                                                                                                                                                                                               
  11                       −1.68         0.018       Heat shock protein HSP 90‐beta                             [P11499](P11499)   Hsp90ab1   Mm.2180         152      32%                 19/24             83 571    4.97
  12                       −1.62         0.018       Alpha‐actinin‐1                                            [Q7TPR4](Q7TPR4)   Actn1      Mm.253564       116      47%                 38/119            103 631   5.23
  13                       −1.59         0.028       Elongation factor 2                                        [P58252](P58252)   Eef2       Mm.326799       78       17%                 14/26             96 222    6.41
  14                       −1.54         0.035       60 kDa heat shock protein, mitochondrial                   [P63038](P63038)   Hspd1      Mm.1777         70       18%                 9/16              61 088    5.91
  11′                      −1.49         0.050       Heat shock protein HSP 90‐beta                             [P11499](P11499)   Hsp90ab1   Mm.2180         121      50%                 30/103            83 571    4.97
  15                       −1.40         0.018       Eukaryotic initiation factor 4A‐I                          [P60843](P60843)   Eif4a1     Mm.371557       86       30%                 12/23             46 353    5.32
  16                       −1.36         0.050       ATP synthase subunit beta, mitochondrial                   [P56480](P56480)   Atp5b      Mm.238973       203      50%                 22/37             56 265    5.19
  13′                      −1.35         0.024       Elongation factor 2                                        [P58252](P58252)   Eef2       Mm.326799       173      45%                 32/72             96 222    6.41
  17                       −1.35         0.039       Mitochondrial import receptor subunit TOM34                [Q9CYG7](Q9CYG7)   Tomm34     Mm.23173        55       39%                 10/86             34 656    9.24
  18                       −1.34         0.020       Heterogeneous nuclear ribonucleoprotein U‐like protein 2   [Q00PI9](Q00PI9)   Hnrnpul2   Mm.476519       69       34%                 23/91             85 515    4.83
  19                       −1.33         0.047       Eukaryotic translation initiation factor 5A‐1              [P63242](P63242)   Eif5a      Mm.29324        84       60%                 9/67              17 049    5.08
  20                       −1.30         0.031       Heat shock cognate 71 kDa protein                          [P63017](P63017)   Hspa8      Mm.290774       76       20%                 13/32             71 055    5.37
  21                       −1.30         0.049       40S ribosomal protein SA                                   [P14206](P14206)   Rpsa       Mm.4071         105      46%                 13/68             32 931    4.80
  22                       −1.29         0.049       Fibrinogen beta chain                                      [Q8K0E8](Q8K0E8)   Fgb        Mm.30063        76       42%                 16/66             55 402    6.68
  23                       −1.25         0.035       T‐complex protein 1 subunit epsilon                        [P80316](P80316)   Cct5       Mm.282158       98       31%                 14/26             60 042    5.72
  24                       −1.22         0.018       Glycine‐tRNA ligase                                        [Q9CZD3](Q9CZD3)   Gars       Mm.250004       97       40%                 24/96             82 624    6.24
  25                       −1.11         0.043       [l]{.smallcaps}‐lactate dehydrogenase A chain              [P06151](P06151)   Ldha       Mm.29324        98       30%                 10/19             36 817    7.62
  26                       −1.10         0.042       Bifunctional purine biosynthesis protein PURH              [Q9CWJ9](Q9CWJ9)   Atic       Mm.38010        132      54%                 28/91             64 690    6.30
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![Fasting‐induced protein remodeling in the spleen. Fluorescent 2D DIGE was performed on spleen homogenates from *ad libitum*‐fed (AL) and 2‐day fasted (F2) mice. (A) Representative fluorescent gel image in which proteins upregulated by fasting are labeled in red and those downregulated are in green. (B) Quantitative profiling of the above image by DeCyder. (C) The three highest scoring upstream regulators (TP53, NFKBIA, and RARB) listed by IPA of the samples from AL and F2 mice (*n* = 4 each). Refer to Fig. [2](#feb412497-fig-0002){ref-type="fig"} legend for detailed information.](FEB4-8-1524-g005){#feb412497-fig-0005}

###### 

Protein expression changes upon 48‐h fasting in mouse spleen

  Spleen spot ID                             Fold change        *P*‐ value   Protein name                                         Uniprot ID         Gene name   Unigene ID   Mascot score   Sequence coverage   Peptide matches   MW        p*I*
  ------------------------------------------ ------------------ ------------ ---------------------------------------------------- ------------------ ----------- ------------ -------------- ------------------- ----------------- --------- ------
  Upregulated proteins                                                                                                                                                                                                                       
  1                                          1.68               0.007        Apolipoprotein A‐I                                   [Q00623](Q00623)   Apoa1       Mm.26743     120            51%                 18/60             30 597    5.51
  2                                          1.37               0.018        Keratin, type II cytoskeletal 8                      [P11679](P11679)   Krt8        Mm.358618    193            70%                 43/128            54 531    5.70
  3                                          1.33               0.043        Glutathione *S*‐transferase μ1                       [P10649](P10649)   Gstm1       Mm.37199     107            77%                 24/107            26 067    7.71
  4                                          1.23               0.020        Adenosine deaminase                                  [P03958](P03958)   Ada         Mm.388       64             55%                 14/77             40 251    5.48
  5                                          1.23               0.030        Mixture: Alpha‐actinin‐1                             [Q7TPR4](Q7TPR4)   Actn1       Mm.253564    185            63%                 50/132            103 631   5.23
  Mixture: Alpha‐actinin‐4                   [P57780](P57780)   Actn4        Mm.81144                                             168                55%         44/132       105 368        5.25                                            
  Downregulated proteins                                                                                                                                                                                                                     
  6                                          −1.62              0.030        Carbonic anhydrase 2                                 [P00920](P00920)   Ca2         Mm.239871    70             60%                 9/51              29 129    6.49
  7                                          −1.36              0.007        Mixture: Heat shock protein HSP 90‐beta              [P11499](P11499)   Hsp90ab     Mm.222       191            58%                 39/99             83 571    4.97
  Mixture: Heat shock protein HSP 90‐alpha   [P07901](P07901)   Hsp90aa1     Mm.341186                                            127                53%         32/99        85 134         4.93                                            
  8                                          −1.30              0.034        Signal transducer and activator of transcription 1   [P42225](P42225)   Stat1       Mm.277406    73             30%                 18/59             87 826    5.42
  9                                          −1.27              0.006        Ribonuclease inhibitor                               [Q91VI7](Q91VI7)   Rnh1        Mm.10152     133            68%                 21/76             51 495    4.69
  10                                         −1.23              0.030        Ezrin                                                [P26040](P26040)   Ezr         Mm.277812    118            57%                 36/99             69 478    5.83
  11                                         −1.21              0.030        Glutaredoxin‐3                                       [Q9CQM9](Q9CQM9)   Glrx3       Mm.267692    76             43%                 12/75             38 039    5.42
  12                                         −1.20              0.030        40S ribosomal protein SA                             [P14206](P14206)   Rpsa        Mm.4071      147            58%                 19/85             32 931    4.80
  13                                         −1.16              0.012        Keratin, type I cytoskeletal 18                      [P05784](P05784)   Krt18       Mm.22479     129            66%                 24/85             47 509    5.22
  14                                         −1.12              0.030        Aconitate hydratase, mitochondrial                   [Q99KI0](Q99KI0)   Aco2        Mm.154581    234            55%                 40/106            86 151    8.08
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When differentially expressed proteins (upon fasting) were classified by the biological processes involved and molecular functions using PANTHER software, both classification patterns were quite similar between the liver and kidney and between the thymus and spleen (Fig. [6](#feb412497-fig-0006){ref-type="fig"}).

![Venn diagrams for clarification of identified proteins that are involved in various biological processes and molecular functions. Fasting‐regulated proteins in the liver, kidney, thymus, and spleen are categorized by 'biological process' or 'molecular function' using PANTHER software.](FEB4-8-1524-g006){#feb412497-fig-0006}

Protein expression changes in the brain and testis {#feb412497-sec-0014}
--------------------------------------------------

Two‐day fasting induced only 2.7% and 9.2% weight losses in the brain and testis, respectively [20](#feb412497-bib-0020){ref-type="ref"}. No apparent protein degradation systems were found to be activated in either organ in our previous RT‐PCR analysis [20](#feb412497-bib-0020){ref-type="ref"}. In representative 2D gels, among a total of 2189 spots detected in the brain (Fig. [7](#feb412497-fig-0007){ref-type="fig"}A), 360 (16.4%, red circles) and 337 (15.4%, green circles) spots were found to be up‐ or downregulated, respectively (Fig. [7](#feb412497-fig-0007){ref-type="fig"}B), and among a total of 2301 spots detected in the testis (Fig. [7](#feb412497-fig-0007){ref-type="fig"}C), 184 (8.0%, red circles) and 249 (10.8%, green circles) spots were found to be up‐ or downregulated, respectively (Fig. [7](#feb412497-fig-0007){ref-type="fig"}D). However, the DeCyder comparative analysis of four AL and four F2 brain (and testis) samples revealed no consistent alterations in protein expression.

![Fasting‐induced protein remodeling in the brain and testis. Fluorescent 2D DIGE was performed on brain (A and B) and testis (C and D) homogenates from *ad libitum*‐fed (AL) and 2‐day fasted (F2) mice. (A and C) Representative fluorescent images, in which proteins upregulated by fasting are labeled in red and those downregulated are in green. (B and D) Quantitative profiling of the above images using DeCyder software. Refer to Fig. [2](#feb412497-fig-0002){ref-type="fig"} legend for detailed information.](FEB4-8-1524-g007){#feb412497-fig-0007}

Discussion {#feb412497-sec-0015}
==========

This study investigated global protein expression changes in six major mouse organs upon 2‐day fasting. After 1‐ or 2‐day fasting, blood levels of glucose, insulin, and C‐peptide 2 (another component of proinsulin \[insulin + C‐peptide 2\] that has its own physiological properties [25](#feb412497-bib-0025){ref-type="ref"}) were significantly reduced compared with the levels in AL mice (67.1%, 61.3%, and 66.3%, respectively \[Fig. [1](#feb412497-fig-0001){ref-type="fig"}\]). Moreover, the levels of two adipose‐derived peptide hormones, leptin (the pleiotropic hormone of satiation signals/energy expenditure [26](#feb412497-bib-0026){ref-type="ref"}, [27](#feb412497-bib-0027){ref-type="ref"}) and resistin (the hormone that may 'resist' insulin actions [28](#feb412497-bib-0028){ref-type="ref"}), were decreased to the same extent in F1 and F2 mice (Fig. [1](#feb412497-fig-0001){ref-type="fig"}). In contrast, ketone bodies and GIP became more accumulated in F2 mice (Fig. [1](#feb412497-fig-0001){ref-type="fig"}). High accumulation of ketone bodies may reflect a progressive systemic energy shift from glucose to ketone bodies. GIP is a polypeptide inhibitor of gastric acid secretion and acts as an affective promotor of insulin secretion [29](#feb412497-bib-0029){ref-type="ref"}; therefore, its elevation could be a delayed compensatory action against low plasma levels of insulin (Fig. [1](#feb412497-fig-0001){ref-type="fig"}). These data indicated somewhat altered systemic conditions between F1 and F2 mice. We identified 72, 26, 14, and 32 proteins that were significantly up‐ or downregulated in the liver, thymus, spleen, and kidney of F2 mice, respectively, but significant expression changes were not found in F1 mice (data not shown).

Previous studies demonstrated the pivotal roles of PPARα in mediating adaptive responses to fasting in the liver (Fig. [2](#feb412497-fig-0002){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]), as observed in the present study; PPARα positively regulates gluconeogenesis, peroxisomal/mitochondrial β‐oxidation, fatty acid transport, and ketogenesis and also negatively regulates glycolysis, amino acid metabolism, and inflammation, by binding to specific nucleotide sequences known as peroxisome proliferator response elements (PPREs) in the promoter regions of target genes [23](#feb412497-bib-0023){ref-type="ref"}, [24](#feb412497-bib-0024){ref-type="ref"}. PPARα‐knockout mice have been shown to display several dysregulated responses such as severe hypoglycemia, hypoketonemia, elevated plasma free fatty acid levels, and fatty liver upon fasting [4](#feb412497-bib-0004){ref-type="ref"}, [5](#feb412497-bib-0005){ref-type="ref"}. Accordingly, we found hepatic upregulation of enzymes involved in gluconeogenesis (Pck1 and Pc), lipid β‐oxidation (Acox1), ketogenesis (Hmgcs2), and downregulation of the enzymes involved in fatty acid synthesis (Fasn) and glycogenolysis (Pygl) (Fig. [2](#feb412497-fig-0002){ref-type="fig"}C, Table [1](#feb412497-tbl-0001){ref-type="table"}, and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet A\]). Although all genes encoding these 'upregulated' proteins have been shown to contain PPREs in their promoter regions [30](#feb412497-bib-0030){ref-type="ref"}, [31](#feb412497-bib-0031){ref-type="ref"}, [32](#feb412497-bib-0032){ref-type="ref"}, [33](#feb412497-bib-0033){ref-type="ref"}, [34](#feb412497-bib-0034){ref-type="ref"} and thus can be activated directly by ligand‐bound PPARα, the suppression of Fasn and Pygl expression could be caused by a secondary mechanism such as low plasma levels of insulin [35](#feb412497-bib-0035){ref-type="ref"}, [36](#feb412497-bib-0036){ref-type="ref"}.

PPARα is activated by both endogenous and synthetic ligands; the former includes long‐chain polyunsaturated fatty acids and eicosanoids such as leukotriene B~4~ and the latter includes fibrates such as fenofibrate, bezafibrate, and clinofibrate, the drugs for the treatment of hypertriglyceridemia [24](#feb412497-bib-0024){ref-type="ref"}. Endogenous ligand activation of PPARα could occur in other PPARα‐expressing organs such as kidney and heart [37](#feb412497-bib-0037){ref-type="ref"} because large amounts of free fatty acids enter the systemic circulation during fasting. Indeed, we found PPARα regulation of nine proteins in the kidney of F2 mice (Fig [3](#feb412497-fig-0003){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet B\]) although the regulatory genes and directions were not necessarily identical to the liver (Figs. [2](#feb412497-fig-0002){ref-type="fig"}C and [3](#feb412497-fig-0003){ref-type="fig"}C). The upstream regulator analysis listed NR1I2 and PPARγ as the second and third highest scoring transcriptional regulators, respectively, but their *P*‐values were much (7--8 orders) higher than PPARα (Fig. [2](#feb412497-fig-0002){ref-type="fig"}C and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]). Expression of PPARγ was rather restricted to adipose tissue and the immune systems, and its hepatic expression was shown to be extremely low compared with PPARα in adult rats [37](#feb412497-bib-0037){ref-type="ref"}.

The highest scoring regulator in the kidney of F2 mice was ATF6, which could regulate the expression of five proteins (Fig. [3](#feb412497-fig-0003){ref-type="fig"}C): Calr, Hsp90b1, Pck1 (spot 1), Acox1 (spot 3), and Cpt2 (carnitine *O*‐palmitoyltransferase 2, mitochondrial; spot 6; an enzyme involved in acyl transfer across the mitochondrial inner membrane for β‐oxidation in the matrix) (Fig. [3](#feb412497-fig-0003){ref-type="fig"}A,B, Table [2](#feb412497-tbl-0002){ref-type="table"}, and Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet B\]). Although the upregulation of Pck1/Acox1/Cpt2 was common between liver and kidney, the two major organs for both gluconeogenesis and β‐oxidation (Figs. [2](#feb412497-fig-0002){ref-type="fig"}C and [3](#feb412497-fig-0003){ref-type="fig"}C), the downregulation of Calr and Hsp90b1 was rather kidney‐specific, which may place ATF6 upstream of PPARα in IPA analysis (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet B\]). ATF6 is an endoplasmic reticulum stress‐regulated transmembrane transcriptional factor that is activated by its proteolytic cleavage with site 1 and site 2 proteases; the resultant cytosolic portion translocates to the nucleus, binds to ER stress response elements, and induces ER stress‐responsive genes [38](#feb412497-bib-0038){ref-type="ref"}. Recent evidence indicates that the interruption of hepatocellular autophagy attenuates the ATF6‐mediated unfolded protein response [39](#feb412497-bib-0039){ref-type="ref"}; thus, conversely, renal autophagy during fasting might induce ATF6 activation. In addition, KLF15, a member of the Krüppel‐like family of transcriptional factors, has been shown to regulate gluconeogenesis and KLF15‐deficient mice displayed severe hypoglycemia after overnight fasting [40](#feb412497-bib-0040){ref-type="ref"}; accordingly, 2‐day fasting induced KLF15 in two gluconeogenic organs, the liver (71st highest score) and the kidney (third highest score) (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A and B\]).

The other major finding of this study was TP53‐mediated transcriptional regulation in the thymus, spleen, and liver; TP53 was listed as the second, first, and fourth highest scoring upstream regulator, respectively (Figs. [4](#feb412497-fig-0004){ref-type="fig"}C and [5](#feb412497-fig-0005){ref-type="fig"}C; Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A, C, and D\]). TP53 has been described as 'the guardian of the genome' because it regulates 'thousands [41](#feb412497-bib-0041){ref-type="ref"}' of target genes to prevent genome mutation and is encoded by the most frequently mutated gene in human cancer; however, TP53 also regulates multiple cellular responses including autophagy [42](#feb412497-bib-0042){ref-type="ref"}, inflammation, pluripotency, and energy metabolism [43](#feb412497-bib-0043){ref-type="ref"}, [44](#feb412497-bib-0044){ref-type="ref"}. A recent study mentioned that fasting robustly increases (stabilizes) TP53 in the mouse liver via hepatocyte autonomous and AMP‐activated protein kinase‐dependent posttranscriptional mechanisms, thereby regulating gluconeogenesis and amino acid catabolism [8](#feb412497-bib-0008){ref-type="ref"}. In addition, TP53‐deleted mice became hypoglycemic and showed defective utilization of hepatic amino acids upon fasting [8](#feb412497-bib-0008){ref-type="ref"}. Of note, TP53 regulated somewhat different sets of genes in the thymus and spleen. Two‐day fasting upregulated five proteins (Krt8/18 \[keratin, type II cytoskeletal 8/18\], Anxa4 \[annexin A4\], Actb \[actin, cytoplasmic 1\], Serpinb6 \[serpin B6\], and Gsn \[gelsolin\]), and downregulated five proteins (Hsp90ab1 \[heat shock protein HSP 90‐beta\], Actn1 \[alpha‐actinin‐1\], Hspd1 \[60 kDa heat shock protein, mitochondrial\], Hspa8 \[heat shock cognate 71 kDa protein\], Rpsa \[40S ribosomal protein SA\], and Ldha \[[l]{.smallcaps}‐lactate dehydrogenase A chain\]) in the thymus (Fig. [4](#feb412497-fig-0004){ref-type="fig"}C, Table [3](#feb412497-tbl-0003){ref-type="table"}, and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet C\]). In contrast, the fasting upregulated five proteins (Apoa1 \[apolipoprotein A‐I\], Krt8, Gstm5 \[= Gstm1, glutathione *S*‐transferase Mu 1\], Ada \[adenosine deaminase\], and Actn1/4 \[mixtures of alpha‐actinin 1/4\], and downregulated six proteins (Hsp90ab/aa1 \[mixtures of heat shock protein HSP 90‐beta/alpha\], Stat 1 \[signal transducer and activator of transcription 1\], Ezr \[ezrin\], Rpsa, Krt18, and Aco2 \[aconitate hydratase, mitochondrial\] in the spleen (Fig. [5](#feb412497-fig-0005){ref-type="fig"}C, Table [4](#feb412497-tbl-0004){ref-type="table"}, and Table [S1](#feb412497-sup-0001){ref-type="supplementary-material"} \[Sheet D\]). In the spleen, nearly half of the proteins with altered expression during fasting were TP53 target gene proteins, which may place TP53 at the top of the upstream regulator lists (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet D\]). Furthermore, TP53 regulation of 12 proteins (among 19 proteins identified) was liver‐specific (Table [S2](#feb412497-sup-0002){ref-type="supplementary-material"} \[Sheet A\]). Fasting/calorie restriction has been also shown to reduce age‐related diseases including cancer [45](#feb412497-bib-0045){ref-type="ref"}; and therefore, fasting‐induced TP53 regulation could be involved in such systemic tumor suppression.

MYCN and HTT were listed as the first and third highest scoring upstream regulators in the thymus (Fig. [4](#feb412497-fig-0004){ref-type="fig"}C), where NFKBIA and RARB were as the second and third highest scoring upstream regulators in the spleen (Fig. [5](#feb412497-fig-0005){ref-type="fig"}C). However, they only regulated only 6, 7, 5, and 3 proteins, respectively, in the IPA analysis, and their physiological roles await further investigations. In conclusion, this proteomic study revealed protein remodeling in response to fasting in the mouse liver, kidney, thymus, and spleen that could be transcriptionally regulated by PPARα and/or TP53. These findings could open new perspectives to understating the systemic effects of single fasting in animal experiments.
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**Table S1.** (A) Liver: Differentially expressed proteins upon 2‐day fasting identified by 2D DIGE and MALDI‐TOF/MS analyses. (B) Kidney: Differentially expressed proteins upon 2‐day fasting identified by 2D DIGE and MALDI‐TOF/MS analyses. (C) Thymus: Differentially expressed proteins upon 2‐day fasting identified by 2D DIGE and MALDI‐TOF/MS analyses. (D) Spleen: Differentially expressed proteins upon 2‐day fasting identified by 2D DIGE and MALDI‐TOF/MS analyses.

###### 

Click here for additional data file.

###### 

**Table S2.** (A) Liver: Upstream regulator analysis of differentially expressed proteins upon 2‐day fasting by Ingenuity Pathway Analysis (IPA). (B) Kidney: Upstream regulator analysis of differentially expressed proteins upon 2‐day fasting by Ingenuity Pathway Analysis (IPA). (C) Thymus: Upstream regulator analysis of differentially expressed proteins upon 2‐day fasting by Ingenuity Pathway Analysis (IPA). (D) Spleen: Upstream regulator analysis of differentially expressed proteins upon 2‐day fasting by Ingenuity Pathway Analysis (IPA).

###### 

Click here for additional data file.
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